Dr. Kris Discusses the Imatinib GIST Clinical Trial

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center Discusses the Imatinib (Gleevec) gastrointestinal stromal tumors (GIST) Clinical Trial.

Dr. Kris says in a GIST clinical trial, researchers compared one year of adjuvant post-surgery imatinib to three years of adjuvant post-surgery imatinib and found a significant improvement in cancer free survival and in overall survival. By taking a medicine for two more years (four pills a day), patients stayed free of cancer and lived longer.